Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Wai Yuen Tong Medicine Holdings's share price is HK$0.33.
Wai Yuen Tong Medicine Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was HK$0.61. Hence, Wai Yuen Tong Medicine Holdings's PS Ratio for today is 0.54.
Good Sign:
Wai Yuen Tong Medicine Holdings Ltd stock PS Ratio (=0.5) is close to 1-year low of 0.46.
The historical rank and industry rank for Wai Yuen Tong Medicine Holdings's PS Ratio or its related term are showing as below:
HKSE:00897'
s PS Ratio Range Over the Past 10 Years
Min: 0.05 Med: 0.13 Max: 0.72
Current: 0.53
During the past 13 years, Wai Yuen Tong Medicine Holdings's highest PS Ratio was 0.72. The lowest was 0.05. And the median was 0.13.
HKSE:00897's PS Ratio is ranked better than 86.9% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.31
vs HKSE:00897: 0.53
During the past 13 years, Wai Yuen Tong Medicine Holdings's highest 3-Year average Revenue per Share Growth Rate was 46.90% per year. The lowest was -71.20% per year. And the median was -19.80% per year.
Wai Yuen Tong Medicine Holdings (HKSE:00897) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Wai Yuen Tong Medicine Holdings PS Ratio Related Terms
Wai Yuen Tong Medicine Holdings PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wai Yuen Tong Medicine Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wai Yuen Tong Medicine Holdings PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wai Yuen Tong Medicine Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Wai Yuen Tong Medicine Holdings's PS Ratio falls into.
Wai Yuen Tong Medicine Holdings PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Wai Yuen Tong Medicine Holdings's Share Price of today is HK$0.33.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Wai Yuen Tong Medicine Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was HK$0.61.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Wai Yuen Tong Medicine Holdings (HKSE:00897) has a PS Ratio of 0.54 as of Sep. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. This is 315% above median its historical median of 0.13. Over the past decade, Wai Yuen Tong Medicine Holdings' PS Ratio has ranged from 0.05 to 0.72. According to the industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #125 out of 954 companies in the Drug Manufacturers industry, placing it in the top 13.1%.
Is Wai Yuen Tong Medicine Holdings' PS Ratio too high?
Wai Yuen Tong Medicine Holdings' current PS Ratio of 0.54 is 315% above median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.72. The Drug Manufacturers industry median PS Ratio is 2.31. Wai Yuen Tong Medicine Holdings' value of 0.54 is 76.6% below this industry median. Based on the distribution chart, Wai Yuen Tong Medicine Holdings ranks #125 out of 954 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Wai Yuen Tong Medicine Holdings has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wai Yuen Tong Medicine Holdings' PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #125 out of 954 companies for PS Ratio. This places Wai Yuen Tong Medicine Holdings in the top 13% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.31. Wai Yuen Tong Medicine Holdings' value of 0.54 is 76.6% below this benchmark. Historically, Wai Yuen Tong Medicine Holdings' own PS Ratio has ranged from 0.05 to 0.72 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 2.31, Wai Yuen Tong Medicine Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.31, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wai Yuen Tong Medicine Holdings's current PS Ratio of 0.54 is 76.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wai Yuen Tong Medicine Holdings's current PS Ratio is 0.54, which is 315% above median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wai Yuen Tong Medicine Holdings stock overvalued right now?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings (HKSE:00897) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.33 — trading 13.8% above its estimated fair value. The current PS Ratio is 0.54, which is 315% above median its 10-year median of 0.13 and 76.6% below the Drug Manufacturers industry median of 2.31. Wai Yuen Tong Medicine Holdings' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Wai Yuen Tong Medicine Holdings (HKSE:00897), the current PS Ratio is 0.54 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wai Yuen Tong Medicine Holdings (HKSE:00897) Overvalued in 2026?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings stock appears to be overvalued.
The current stock price of HK$0.33 is trading 13.8% above its estimated GF Value™ of HK$0.29.
GuruFocus considers Wai Yuen Tong Medicine Holdings to be Modestly Overvalued.
Key valuation signals for HKSE:00897:
PS Ratio: 0.54 (315% above median its 10-year median of 0.13)
GF Value™: HK$0.29 vs. price of HK$0.33 (13.8% above fair value)
Industry Position: 76.6% below the Drug Manufacturers median (#125 of 954)
No single metric tells the full story. See the HKSE:00897 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.
34GF Score
Get the complete analysis for HKSE:00897
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00897 has been successfully added to your 
